Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

Study acronym: EvoPAR-PR05
StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 6 more changesShow less
    • Trial sites expanded: 2 → 210 locations
    • Primary completion date: Jun 17, 2031 to May 30, 2031
    • Study completion date: Jun 14, 2033 to May 27, 2033
    • Start date changed from estimate of Oct 1, 2026 to Sep 15, 2026
    • Eligibility criteria expanded, about 32 words
    • Secondary endpoints: details revised at 4 of 12 entries
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
AstraZeneca
729 trials monitored
See 62 trials at risk
Prostate Cancer
2,550 trials monitored
See 165 trials at risk
The primary objective of this study is to measure efficacy of saruparib + physician's choice of ARPI compared with placebo + ARPI in men with metastatic hormone-sensitive prostate cancer (mHSPC) who have previously received docetaxel chemotherapy or a prostate-specific membrane antigen (PSMA)-directed lutetium-177 radioligand therapy with no evidence of disease progression and PSA ≥ 0.2 ng/mL.
Trial Details
NCT Number NCT07711002
Lead Sponsor AstraZeneca
Conditions
(from sponsor)		 Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Related terms Prostatic Neoplasms
Enrollment 1,330 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov